Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors: High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 2, 2007, Pages 92-100

  Kobayashi, Fumiyoshi ^a   Yageta, Yuichi ^a   Segawa, Mitsuru ^a   Matsuzawa, Shigeki ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Acetylcholine release; Anti cholinergics; CAS 170105 16 5; Imidafenacin; KRP 197; ONO 8025; Overactive bladder; Salivary gland; Urinary bladder

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; IMIDAFENACIN; KRP 197; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; ONO 8025; OXYBUTYNIN; POTASSIUM; PROPIVERINE; TOLTERODINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MALE; NONHUMAN; OVERACTIVE BLADDER; POTASSIUM TRANSPORT; RAT; SALIVARY GLAND;

EID: 33847051893     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296589     Document Type: Article

References (23)

1. Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urology. 2003;43:1-5.
2. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60 (Suppl 5A):82-89.
3. Goyal RK. Muscarinic receptor subtypes. Physiology and clinical implications. New Engl J Med. 1989;321:1022-1029.
4. Eglen RM, Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol. 1996;78:59-68.
5. Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3: 46-53.
6. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995;273:959-966.
7. Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci. USA 2000;97:9579-9584.
8. 3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther. 2004;310:1255-1265.
9. Somogyi GT, de Groat WC. Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J Auton Nerv Sys. 1992;37:89-98.
10. 2 inhibitory muscarinic receptors mediate rat bladder contractility. Am J Physiol. 1998;274:R517-R523.
11. Miyachi H, Kiyota H, Segawa M. Design, synthesis and antimuscarinic activity of some imidazolium derivatives. Bio Med Chem Lett. 1999;9:3003-3008.
12. Miyachi H, Kiyota H, Uchiki H, Segawa M. Synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. Bio Med Chem. 1999;7:1151-1161.
13. Kanayama N, Kobayashi C, Masuda Y, Ohmori S, Kusajima H, Ooie T. In vitro metabolism of imidafenacin and its potential in the inhibition of human cytochrome P450 enzymes. Drug Metab Rev. 2005;37 (Suppl. 2):127-128.
14. 3 antagonists for clinical use. Life Sci. 1997;60:1053-1060.
15. Nilvebrant L, Andersson KE, Gillberg P-G, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997;327:195-207.
16. Nilvebrant L, Hallén B, Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997;60:1129-1136.
17. 2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol. 1998;275:R1654-R1660.
18. Caulfield MP, Birdsall NJM. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279-290.
19. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-affernt pathways. Urology. 2005;65:238-242.
20. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004;63 (Suppl 3A):17-23.
21. Gallacher DV, Petersen OH. Electrophysiology of mouse parotid acini: effects of electrical field stimulation and ionophoresis of neurotransmitters. J Physiol 1980;305:43-57.
22. Dunèr-Engström M, Larsson O. Fredholm, BB. Continuous monitoring of potassium efflux from rat parotid gland fragments by potassium selective electrodes. Acta Physiol Scand. 1986;126:551-555.
23. 3 muscarinic receptor single- and double-knockout mice. Mol Pharmacol. 2004;66:260-267.